Results 131 to 140 of about 805,984 (229)

GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half‐life in a murine model of sickle cell disease

British Journal of Haematology, 2016
D. Oksenberg, K. Dufu, Mira P Patel, Chihyuan Chuang, Zhe Li, Qing Xu, Abel Silva-García, Chengjing Zhou, A. Hutchaleelaha, L. Patskovska, Y. Patskovsky, S. Almo, U. Sinha, B. Metcalf, D. Archer   +14 more
semanticscholar   +1 more source

High-Throughput Physiologically Based Pharmacokinetic Model for Rodent Pharmacokinetics Prediction Using Machine Learning-Predicted Inputs and a Large <i>In Vivo</i> Pharmacokinetics Data Set. [PDF]

Mol Pharm
Bassani D, Andrews-Morger A, Zhang J, Docci L, Cecere G, Pähler A, Belubbi T, Laye P, Shih I, Parrott NJ.   +9 more
europepmc   +1 more source

<i>In vivo</i> Expansion of Regulatory T cells via an Engineered IL-2 Mutein to Suppress Autoimmune Glomerulonephritis. [PDF]

Theranostics
Kuang H, Lin CX, Huang J, Li WX, Zhu YG, Jiang N, Li Z, Li N, Li P, Jia XY, Cui Z, Zhao MH.   +11 more
europepmc   +1 more source

Genome-wide maps of CPD deamination in yeast reveal the impact of DNA sequence context and nucleosome architecture on cytosine deamination rates. [PDF]

Genome Res
Laughery MF, Stark B, Morledge-Hampton B, Roberts SA, Wyrick JJ.   +4 more
europepmc   +1 more source

A modular "Catch-and-Play" platform for rapid T-cell engager target assembly for personalised cancer treatment. [PDF]

Signal Transduct Target Ther
Xi X, Zhang Y, Zhao D, Chen F, Howard KA.   +4 more
europepmc   +1 more source

Inhibition of acalabrutinib metabolism by finerenone and its molecular docking studies. [PDF]

Cell Biol Toxicol
Wang P, Fu H, Wu J, Li R, Cao L, Xu RA, Lin W.   +6 more
europepmc   +1 more source

Unexpected Clinical Drug-Drug Interaction of Fexinidazole on Midazolam Pharmacokinetics: Insights into Underlying Mechanisms from Clinical Phase I Study Results and Supporting In Vivo/Vitro Evidence. [PDF]

Clin Drug Investig
Gassiot M, Brun P, Wauthier V, Da Silva F, Nicolas O, Hays S, Sultan E.   +6 more
europepmc   +1 more source

Intracellular half-life of cisplatin in malignant cells : A kinetic study of the decline rate of intracellular cisplatin concentration in in-vitro grown cells determined by LC-ICP-MS following exposure to clinically relevant cisplatin doses

, 2011
Cisplatin is a common cancer therapy substance used against several types of malignant tumors and often shows great efficiency. The most important tumour killing mechanism is believed to be formation of Pt-DNA adducts. It is however a common phenomenon that tumors develop resistance causing inefficient treatment.
openaire   +1 more source

A highly potent and broadly accessible bispecific nanobody for the treatment of ebola virus infections. [PDF]

PLoS Pathog
Bu F, Ye G, Morsheimer K, Turner-Hubbard H, Eaton B, Anantpadma M, Bheemanapally K, Tan C, Davey R, Li F.   +9 more
europepmc   +1 more source

Subunit fusion unlocks rapid <i>in vitro</i> maturation for slowly activating heterodimeric [FeFe]-hydrogenases. [PDF]

Chem Sci
Jaenecke J, Bikbaev K, Malagnini M, Bronold J, Yadav S, Apfel UP, Léger C, Birrell JA, Span I, Plumeré N, Winkler M.   +10 more
europepmc   +1 more source